Waters Corporation $WAT Shares Acquired by Logan Capital Management Inc.

Logan Capital Management Inc. increased its position in shares of Waters Corporation (NYSE:WAT) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,790 shares of the medical instruments supplier’s stock after purchasing an additional 2,502 shares during the period. Logan Capital Management Inc. owned 0.06% of Waters worth $14,354,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in WAT. Zions Bancorporation National Association UT lifted its holdings in shares of Waters by 121.2% in the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 40 shares during the period. ANTIPODES PARTNERS Ltd acquired a new position in Waters during the third quarter worth about $26,000. Hantz Financial Services Inc. raised its position in Waters by 115.4% in the third quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 60 shares in the last quarter. eCIO Inc. bought a new stake in Waters in the fourth quarter worth about $49,000. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its holdings in Waters by 28.3% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 163 shares of the medical instruments supplier’s stock valued at $62,000 after acquiring an additional 36 shares during the last quarter. 94.01% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Waters news, Director Wei Jiang acquired 500 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was purchased at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the transaction, the director owned 3,441 shares of the company’s stock, valued at $996,031.86. The trade was a 17.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

WAT has been the topic of several recent research reports. Wolfe Research assumed coverage on shares of Waters in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price objective on the stock. Robert W. Baird set a $387.00 target price on shares of Waters in a report on Wednesday, May 6th. The Goldman Sachs Group raised Waters to a “strong-buy” rating in a report on Wednesday, April 1st. UBS Group increased their price objective on Waters from $330.00 to $375.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Finally, Barclays lifted their target price on Waters from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Waters currently has a consensus rating of “Moderate Buy” and an average price target of $394.56.

Waters Trading Down 0.9%

NYSE WAT opened at $359.80 on Friday. The firm’s 50 day moving average price is $336.59 and its two-hundred day moving average price is $350.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15. The stock has a market cap of $35.33 billion, a price-to-earnings ratio of 45.72, a PEG ratio of 2.20 and a beta of 1.21.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the consensus estimate of $2.31 by $0.39. Waters had a return on equity of 15.60% and a net margin of 11.91%.The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter last year, the firm posted $2.25 earnings per share. Waters’s revenue was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts anticipate that Waters Corporation will post 14.5 EPS for the current year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.